Advertisement
Brief Report|Articles in Press, 100486

Brief Report: Prognostic relevance of 3q amplification in squamous cell carcinoma of the lung

Open AccessPublished:February 28, 2023DOI:https://doi.org/10.1016/j.jtocrr.2023.100486
Brief Report: Prognostic relevance of 3q amplification in squamous cell carcinoma of the lung
Previous ArticleEarly tumor shrinkage as a predictor of favorable treatment outcomes in patients with extensive stage-small cell lung cancer who received programmed cell death-ligand 1 inhibitor plus platinum-etoposide chemotherapy: A prospective observational study
Next ArticleEfficacy and Safety of Anti-PD-L1 Monoclonal Antibody Socazolimab with Carboplatin and Etoposide for Extensive-Stage Small Cell Lung Cancer: Results from the Phase Ib Clinical Trial
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Introduction

      Amplification of 3q is the most common genetic alteration identified in squamous cell carcinoma of the lung (LUSC), with the most frequent amplified region being 3q26-3q28.

      Methods

      In this analysis, we aim to describe the prognostic relevance of 3q amplification by focusing on a minimal common region (MCR) of amplification constituted of 25 genes. We analyzed 511 cases of LUSC from The Cancer Genome Atlas (TCGA) and included 476 in the final analysis.

      Results

      We identified a 25-gene MCR that was amplified in 221 (44.3%) cases and was associated with better disease specific-survival (DSS) (NR versus 9.25 years; 95% CI [5.24-NR]; log-rank p=0.011) and a progression-free interval (PFI) of 8 years (95% CI [5.1-NR]) versus 4.9 years (95% [3.5-NR]) (Log-rank p=0.020). Multivariable analysis revealed that MCR amplification was associated with improved DSS and PFI.

      Conclusion

      Amplification of the 25-gene MCR within 3q was present in 44% of this cohort, mainly composed of Caucasian patients with early-stage LUSC. This analysis strongly indicates the prognostic relevance of the 25-gene MCR within 3q. We are further evaluating its prognostic and predictive relevance in a racially diverse patient population with advanced LUSC.

      Article info

      Publication history

      Accepted: February 19, 2023
      Received in revised form: February 9, 2023
      Received: October 3, 2022

      Publication stage

      In Press Journal Pre-Proof

      Footnotes

      Disclosure of Conflict of Interest:

      SG reports receiving compensation for participating in advisory boards from Astra-Zeneca, Genentech/Roche, Abbvie, Takeda, Bristo Myers-Squibb, Blueprint, Lilly, Merck, GSK, Daichii, Esai, Pfizer, Janssen, Mirati; and travel support from Merati. He is a member of the Data Safety Monitoring Board of 2 trials sponsored by AstraZeneca. NP serves as a member of an advisory board for AstraZeneca. FA received honoraria from MJH Life Sciences and IntrinsiQ Specialty Solutions. PL, SC, SRKS, RC, and HA had nothing to declare.

      CRediT Statement

      Fawzi Abu Rous: Roles/Writing - original draft, Visualization, Conceptualization

      Pin Li: Formal analysis, Writing - review & editing

      Shannon Carskadon: Data curation, Visualization

      Sunny RK Singh: Writing - Review & Editing, Visualization

      Rebecca Chacko: Writing - Review & Editing

      Hassan Abushukair: Writing - Review & Editing, Data Curation

      Shirish Gadgeel: Methodology, Writing - review & editing, Supervision, Visualization, Conceptualization

      Nallasivam Palanisamy: Conceptualization, Data curation, Methodology, Visualization, Writing - review & editing, Supervision

      Identification

      DOI: https://doi.org/10.1016/j.jtocrr.2023.100486

      Copyright

      © 2023 Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.

      User license

      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article (private use only, not for distribution)
      • Reuse portions or extracts from the article in other works

      Not Permitted

      • Sell or re-use for commercial purposes
      • Distribute translations or adaptations of the article

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX